Kidney Involvement in Multicentric Castleman Disease

American Journal of Kidney Diseases

Volumn 53, Issue 3, 2009, Pages 550-554

  Suneja, Sumeet ^a   Chidambaram, Mala ^a   Herzenberg, Andrew M ^a   Bargman, Joanne M ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Castleman disease; immunosuppressive therapy; interleukin 6; thrombotic microangiopathy

Indexed keywords

ALBUMIN; BENCE JONES PROTEIN; CALCIUM; CREATININE; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ELECTROLYTE; HEMOGLOBIN; IMMUNOGLOBULIN A ANTIBODY; LACTATE DEHYDROGENASE; LIVER ENZYME; PREDNISONE; THIAZIDE DIURETIC AGENT;

ADULT; ALBUMIN BLOOD LEVEL; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ARTICLE; BLOOD PRESSURE MEASUREMENT; BONE MARROW BIOPSY; CALCIUM BLOOD LEVEL; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CREATININE BLOOD LEVEL; ELECTROLYTE BLOOD LEVEL; ELECTRON MICROSCOPY; ERYTHROCYTE SEDIMENTATION RATE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN TISSUE; HYPERTENSION; IMMUNOELECTROPHORESIS; KIDNEY BIOPSY; KIDNEY DISEASE; LACTATE DEHYDROGENASE BLOOD LEVEL; LAPAROTOMY; LEUKOCYTE COUNT; MALE; MEDIASTINUM LYMPH NODE; PHYSICAL EXAMINATION; PLASMACYTOSIS; POLYMERASE CHAIN REACTION; PROTEINURIA; SPLENECTOMY; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT DURATION; URINALYSIS;

GIANT LYMPH NODE HYPERPLASIA; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED;

EID: 60149102793     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2008.08.026     Document Type: Article

References (35)

1. Hengge U.R., Ruzicka T., Tyring S.K., et al. Update on Kaposi's sarcoma and other HHV8 associated diseases. Part 2: Pathogenesis, Castleman's disease, and pleural effusion lymphoma. Lancet Infect Dis 2 (2002) 344-352
2. Shahidi H., Myers J.L., and Kvale P.A. Castleman's disease. Mayo Clin Proc 70 (1995) 969-977
3. Montoli A., Minola E., Stabile F., et al. End-stage\failure from renal amyloidosis of the AA type associated with giant lymph node hyperplasia (Castleman's disease). Am J Nephrol 15 (1995) 142-146
4. Ruggieri G., Barsotti P., Copppola G., et al. Membranous nephropathy associated with giant lymph node hyperplasia. Am J Nephrol 10 (1990) 323-328
5. Seida A., Wada J., Morita Y., et al. Multicentric Castleman's disease associated with glomerular microangiopathy and MPGN-like lesion: Does vascular endothelial cell-derived growth factor play causative or protective roles in renal injury?. Am J Kidney Dis 43 (2004) E3-E9
6. Naka T., Nishimoto N., and Kishimoto T. The paradigm of IL-6: From basic science to medicine. Arthritis Res 4 suppl 3 (2002) S233-S242
7. Levey A.S., Bosch J.P., Lewis J.B., Greene T., Rogers N., Roth D., and Modification of Diet in Renal Disease Study Group. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Ann Intern Med 130 (1999) 461-470
8. Castleman B., Iverson L., and Menendez V.P. Localized mediastinal lymph-node hyperplasia resembling thymoma. Cancer 9 (1956) 822-830
9. Keller A.R., Hochholzer L., and Castleman B. Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer 29 (1972) 670-683
10. Dupin N., Diss T.L., Kellam P., et al. HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. Blood 95 (2000) 1406-1412
11. Hsu S.M., Waldron J.A., Xie S.S., et al. Expression of interleukin-6 in Castleman's disease. Hum Pathol 24 (1993) 833-839
12. Chadburn A., Cesarman E., Nador R.G., et al. Kaposi's sarcoma-associated herpesvirus sequences in benign lymphoid proliferations not associated with human immunodeficiency virus. Cancer 80 (1997) 788-797
13. McCarty M.J., Vukelja S.J., Banks P.M., et al. Angiofollicular lymph node hyperplasia (Castleman's disease). Cancer Treat Rev 21 (1995) 291-310
14. Frizzera G. Castleman's disease and related disorders. Semin Diagn Pathol 5 (1988) 346-364
15. Chan T., Cheng I.K.P., Wong K., et al. Resolution of membranoproliferative glomerulonephritis complicating angiofollicular lymph node hyperplasia (Castleman's disease). Nephron 65 (1993) 628-632
16. Tsukamoto Y., Hanada N., Nomura Y., et al. Rapidly progressive renal failure associated with angiofollicular lymph node hyperplasia. Am J Nephrol 11 (1991) 430-436
17. Summerfield G.P., Taylor W., Bellingham A.J., et al. Hyaline-vascular variant of angiofollicular lymph node hyperplasia with systemic manifestation and response to corticosteroids. J Clin Pathol 36 (1983) 1005-1011
18. Couch W.D. Giant lymph node hyperplasia associated with thrombotic thrombocytopenic purpura. Am J Clin Pathol 74 (1980) 340-344
19. Lajoie G., Kumar S., Min K., et al. Renal thrombotic microangiopathy associated with multicentric Castleman's disease. Am J Surg Pathol 19 (1995) 1021-1028
20. Jones C.H., and Will E.J. Angiofollicular lymph node hyperplasia, accelerated hypertension, and acute renal failure: A case report. Nephrol Dial Transplant 11 (1996) 352-354
21. Coppo P., Veyradier A., Durey M.A., et al. Pathophysiology of thrombotic microangiopathies: Current understanding. Ann Med Interne (Paris) 153 (2002) 153-166
22. Fukatsu A., Ito Y., Yuzawa Y., et al. A case of POEMS syndrome showing elevated serum interleukin 6 and abnormal expression of interleukin 6 in the kidney. Nephron 62 (1992) 47-51
23. Greiner T., Armitage J.O., and Gross T.G. Atypical lymphoproliferative diseases. Hematology (Am Soc Hematol Educ Program) (2000) 133-146 Jan
24. Leger-Ravet M.B., Peuchmaur M., Devergne O., et al. Interleukin-6 gene expression in Castleman's disease. Blood 78 (1991) 2923-2930
25. Yoshizaki K., Matsuda T., Nishimoto N., et al. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood 74 (1989) 1360-1367
26. Brandt S.J., Bodine D.M., Dunbar C.E., et al. Dysregulated interleukin 6 expression produces a syndrome resembling Castleman's disease in mice. J Clin Invest 86 (1990) 592-599
27. Burke G.W., Ciancio G., Cirocco R., et al. Microangiopathy in kidney and simultaneous pancreas/kidney recipients treated with tacrolimus: Evidence of endothelin and cytokine involvement. Transplantation 68 (1999) 1336-1342
28. Litalien C., Proulx F., Mariscalco M.M., et al. Circulating inflammatory cytokine levels in hemolytic uremic syndrome. Pediatr Nephrol 13 (1999) 840-845
29. Wada H., Kaneko T., Ohiwa M., et al. Plasma cytokine levels in thrombotic thrombocytopenic purpura. Am J Hematol 40 (1992) 167-170
30. Greer I.A., Lyall F., Perera T., et al. Increased concentrations of cytokines interleukin-6 and interleukin-1 receptor antagonist in plasma of women with preeclampsia: A mechanism for endothelial dysfunction?. Obstet Gynecol 84 (1994) 937-940
31. Esmon C.T. Possible involvement of cytokines in diffuse intravascular coagulation and thrombosis. Baillieres Best Pract Res Clin Haematol 12 (1999) 343-359
32. Nishi J., Arimura K., Utsunomiya A., et al. Expression of vascular endothelial growth factor in sera and lymph nodes of the plasma cell type of Castleman's disease. Br J Haematol 104 (1999) 482-485
33. Nishi J., and Maruyama I. Increased expression of vascular endothelial growth factor (VEGF) in Castleman's disease: Proposed pathomechanism of vascular proliferation in the affected lymph node. Leuk Lymphoma 38 (2000) 387-394
34. Bernardo A., Ball C., Nolasco L., et al. Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow. Blood 104 (2004) 100-106
35. Shelat S.G., Ai J., Zheng X.L., et al. Molecular biology of ADAMTS13 and diagnostic utility of ADAMTS13 proteolytic activity and inhibitor assays. Semin Thromb Hemost 31 (2005) 659-672